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Abstract 
Background: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a 
beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes and 
mortality in type 2 diabetes mellitus after 5 years of active treatment. However, a beneficial reduction in major CVD 
events was shown in a pre-specified sub-group of participants with dyslipidemia. The extended follow-up of this 
trial provides the opportunity to further investigate possible beneficial effects of fibrates in this group of patients. We 
aimed to evaluate possible “legacy effects” of fibrate add-on therapy on mortality and major cardiovascular outcomes 
in patients with dyslipidemia.
Methods: The ACCORD-lipid study was a randomized controlled trial of 5518 participants assigned to receive sim-
vastatin plus fenofibrate vs simvastatin plus placebo. After randomized treatment allocation had finished at the end 
of the trial, all surviving participants were invited to attend an extended follow-up study (ACCORDION) to continue 
prospective collection of clinical outcomes. We undertook a secondary analysis of trial and post-trial data in patients 
who had dyslipidemia. The primary outcome was all-cause and cardiovascular mortality, and secondary outcomes 
were nonfatal myocardial infarction, stroke, congestive heart failure and major coronary heart disease. We used an 
intention-to-treat approach to analysis to make comparisons between the original randomized treatment groups.
Results: 853 participants with dyslipidemia had survived at the end of the trial. Most participants continued to 
use statins, but few used fibrates in either group during the post-trial period. The incidence rates in the fenofibrate 
group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart 
failure and major coronary heart disease than those in the placebo group over a post-trial follow-up. Allocation to the 
combined fibrate-statin treatment arm during the trial period had a beneficial legacy effect on all-cause mortality 
(adjusted HR = 0.65, 95% CI 0.45–0.94; P = 0.02).
Conclusions: Fibrate treatment during the initial trial period was associated with a legacy benefit of improved 
survival over a post-trial follow-up. These findings support re-evaluation of fibrates as an add-on strategy to statins in 
order to reduce cardiovascular risk in diabetic patients with dyslipidemia.
Trial registration clinicaltrials.gov, Identifier: NCT00000620
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Background
Dyslipidemia is a major contributor to the increased risk 
of cardiovascular disease (CVD) among patients with 
type 2 diabetes mellitus (T2DM). While other types of 
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the typical diabetic dyslipidemia (also called atherogenic 
dyslipidemia) is characterized by elevated triglycerides, 
small dense low-density lipoproteins (LDL) particles, 
and low levels of high-density lipoproteins (HDL) choles-
terol [1]. Recommended first line measures for CVD pre-
vention in people with diabetes who have dyslipidemia 
include non-drug interventions (dietary regulation, exer-
cise, moderation of alcohol intake and weight loss) and 
LDL-cholesterol lowering with statin drug therapy [2, 3]. 
The use of statins as the primary drug treatment option 
is supported by a large body of evidence. For example, 
a meta-analysis of 14 randomized trials which included 
more than 18,000 people with diabetes, found that for 
every mmol/L reduction in LDL cholesterol there was a 
21% proportional reduction in the risk of a major vascu-
lar event [4]. This proportional risk reduction is similar to 
that observed in people without diabetes [5], but because 
the baseline absolute risk is on average higher in people 
with diabetes, the absolute benefits are greater. However, 
the trial data also show substantial “residual risk” in peo-
ple with T2DM who are on statin treatment [6–8], and 
often the absolute risk is still higher than that in people 
without diabetes who are not on statin treatment [9–11]. 
This indicates that preventative treatment with statins 
alone may not be enough in people with T2DM and 
additional therapies may need to be considered. There 
is also evidence from Mendelian randomization studies 
that high triglycerides are causally related to CVD, and 
so drug therapy targeting this lipid abnormality could 
help to further reduce CVD risk in people with T2DM 
[12–14].
Fibrates are an example of such a drug therapy, as they 
both decrease triglyceride levels and increase HDL-C 
[15]. To investigate if these effects on lipid biomarkers 
translates into a reduction in CVD, the Action to Con-
trol Cardiovascular Risk in Diabetes (ACCORD)-Lipid 
study randomized 5518 people with T2DM to combined 
statin-fibrate therapy vs statin therapy alone. Although 
the ACCORD-Lipid study found no benefit between ran-
domized groups overall, a beneficial reduction in major 
CVD events was found in a pre-specified sub-group anal-
ysis of study participants with dyslipidemia (triglycer-
ide greater than 204 mg/dl and high-density lipoprotein 
less 34  mg/dl) [16, 17]. The authors hypothesized that 
fibrate therapy, offered as an add-on to statin therapy, 
may be beneficial for people with diabetes who are found 
have hypertriglyceridemia and/or reduced HDL-C. This 
hypothesis is supported by the findings of several system-
atic reviews of RCTs of fibrate therapy [18–21].
At the end of the ACCORD-Lipid trial, participants 
were unblinded from their randomized groups, and pas-
sively followed up for an additional 5 years through fol-
low-up clinics and routine data collection methods. The 
post-trial follow-up data provide a unique opportunity 
to evaluate the effect of add-on fibrate therapy in the 
longer-term, and the possibility of the emergence of “leg-
acy effects”. Legacy effects describe intervention effects 
observed in the post-trial period which are not due to 
the direct effects observed during the trial period [22]. 
The finding of a legacy effect would have important clini-
cal implications, including the potential benefits of early 
initiation of fibrate treatment in the setting of diabetic 
dyslipidemia. Although potential legacy effects for statin 
treatment have been investigated in a number of post-
trial follow up studies [23], those for combined statin-
fibrate treatment remain unexplored [24, 25]. Post-trial 
data after a statin-fibrate RCT provide the opportunity to 
investigate potential legacy effects in people with T2DM 
and dyslipidemia. Therefore, we conducted a second-
ary analysis of data from the ACCORD-Lipid trial and 
the ACCORDION post-trial follow-up study, in order 
to determine whether or not there is evidence for legacy 




The Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) Trial was a randomized, double 2 × 2 facto-
rial design study, which evaluated the effects of intensive 
glycemic control, intensive blood pressure control, and 
combined fibrate statin treatment, on the prevention 
of cardiovascular disease in people with T2DM [26]. It 
enrolled 10,251 people (mean age 62  years), who had a 
history of T2DM for a median duration of 10 years, with 
mean glycated hemoglobin (HbA1c) level of 8.3%. Par-
ticipants had either a history of previous cardiovascular 
disease or had elevated risk factors levels. The lipid sub-
study was conducted in 5518 of the trial participants. In 
addition to fulfilling the overarching ACCORD entry cri-
teria, the LIPID participants needed to meet all of the fol-
lowing additional criteria: (1) 60 mg/dl < LDL-C < 180 mg/
dl (1.55 to 4.65 mmol/l) if not on a lipid lowering agent 
during screening, or, if on a lipid-lowering agent, the 
LDL-C needed to be between prespecified drug/dose-
specific cut points, and (2) HDL-C less than 55  mg/
dl (1.42  mmol/l) for women or African-Americans, or 
HDL-C less than 50 mg/dl (1.29 mmol/l) for all other gen-
der and ethnic groups, and (3) triglycerides < 750  mg/dl 
(8.47 mmol/l) on no therapy or < 400 mg/dl (4.52 mmol/l) 
on treatment with lipid lowering drugs. Participants 
were randomly assigned to either simvastatin plus fenofi-
brate or simvastatin plus placebo. The starting dose of 
open-labeled simvastatin were determined by presence 
of cardiovascular disease and the dose of masked fenofi-
brate/placebo were determined by calculated glomerular 
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filtration rate at randomization. Further changes to the 
dose of both drugs were made during the trial in accord-
ance to the trial guidelines [16]. At the end of the trial, all 
surviving ACCORD participants who could be contacted 
were invited to enter an observational follow-up study 
(ACCORDION) [27, 28]. No active trial therapy was 
provided in this period, and medical care was provided 
by the participant’s local primary care provider. Data on 
health outcomes (e.g. hospital records, death certificates, 
etc.) and medication usage were collected by phone and 
clinic visits. Physical examinations were conducted at the 
first and last clinic visits, include the collection of urine 
and blood samples for analysis [28].
In the ACCORD-Lipid trial, dyslipidemia was pre-
specified as the combination of the highest tertile of tri-
glyceride (204 mg/dl) and lowest third of HDL-C (34 mg/
dl) at baseline [16]. We used the same definition for dys-
lipidemia in the current analysis. Our primary outcomes 
were all-cause mortality and cardiovascular mortality, 
and our secondary outcomes were nonfatal myocardial 
infarction, stroke, congestive heart failure and a major 
coronary heart disease event [16, 28]. Although there was 
event adjudication during the ACCORD trial, this was 
done in only a randomly selected 10% of events during 
the post-trial follow-up period (for the purpose of qual-
ity control). For consistency across all follow up data, we 
used outcomes reported by site investigators during both 
trial and post-trial period (unadjudicated events).
Statistical methods
Participants’ characteristics at baseline of trial and first 
post-trial visit were summarized for the two randomized 
groups using means, standard deviations, and percent-
ages. The measured lipid levels at each study visit, includ-
ing total cholesterol, triglycerides, HDL-C, LDL-C and 
VLDL-C, were compared between randomized groups. 
VLDL-C was obtained by subtracting HDL-C and LDL-C 
from total cholesterol. Primary and secondary outcomes 
were analyzed according to the intention-to-treat princi-
ple. Hazard ratios (HRs) and 95% confidential intervals 
were estimated using Cox proportional hazards models. 
Kaplan–Meier estimates were used to obtain the pro-
portion of patients who had an event during follow-up. 
The direct effects of treatment were estimated by fitting 
models for the trial period (short term effects), and the 
entire study period (from baseline of trial through to 
end of post-trial, long term effects). The legacy effects of 
treatment were estimated by fitting models for the post-
trial period alone. This analysis was based on survivors 
who consented to additional follow-up, and their follow-
up times were calculated by the difference between full 
follow-up time and censoring time for the trial. These 
analyses were adjusted for age, sex, ethnicity, network, 
education status, CVD history, blood glucose trial treat-
ment assignment and years of diabetes. To examine the 
robustness of these findings, sensitivity analyses were 
undertaken to (i) account for effects of medications taken 
in the post-trial follow-up period, and (ii) to account 
for possible imbalance in confounders between the two 
groups at the start of post-trial follow-up (using inverse 
probability weighting). All analyses were performed with 
R (version 3.5.1).
Results
Characteristics of the participants at baseline and 1st 
post‑trial visit
Of a total of 5518 patients enrolled in the ACCORD Lipid 
trial, 940 (17.0%) were identified as having dyslipidemia. 
484 of them were assigned to fenofibrate and simvastatin 
therapy, and 456 participants received simvastatin and 
placebo. Of these participants, 853 had survived at the 
end of the trial, and 765 (90.0%) consented to enter the 
post-trial follow-up study. The median follow-up time in 
the post-trial period was 4.9  years. Table  1 shows char-
acteristics of the participants at the trial baseline and 
at the first post-trial visit. The mean age at baseline was 
61.8 years, and the fenofibrate group was slightly younger 
than the placebo group. Most of the patients were male 
and about forty percent of patients had a history of CVD 
disease. The HbA1c, blood pressure and lipid levels were 
well matched across treatment groups both at baseline 
and  1st post-trial visit.
Trial adherence and use of lipid‑modifying medication 
after trial
Participants’ adherence during the trial and the use of 
statin/fibrate post-trial is shown in Table  2. The adher-
ence for both simvastatin and fenofibrate/placebo during 
the trial period was high. In the post-trial period, most 
participants continued to use statin therapy, while few 
used fibrates in either group (likely due to the finding of 
no benefit overall in the ACCORD-Lipid study).
Efficacy of fenofibrate in lipid‑modifying
Figure  1 compares the plasma lipids of the two groups 
at each study visit during the within trial and post-
trial periods. During the trial, allocation to fenofibrate 
resulted in improvements in almost all lipids compared 
with placebo, but the largest differences were seen for 
plasma triglyceride concentrations and VLDL-C levels. 
Further, although the differences in HDL-C and LDL-C 
levels between randomized groups decreased over time, 
they were maintained for levels of triglycerides (P = 0.01) 
and VLDL-C (P = 0.006) through to the end of the trial. 
At the first post-trial visit there were minimal differences 
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between randomized groups for any of the lipids, and this 
remained the case through to the last clinic visit.
Clinical outcomes
The incidence rate of the primary and secondary out-
comes and the hazard ratios of allocation to the fenofi-
brate plus simvastatin versus simvastatin alone during 
the ACCORD-lipid trial, ACCORDION and the full fol-
low-up period are shown in Table 3. We found that the 
incidence rates in the fenofibrate group were lower with 
respect to all-cause mortality, CVD mortality, nonfatal 
myocardial infarction, congestive heart failure and major 
coronary heart disease than those in the placebo group 
over the post-trial follow-up. Allocation to the com-
bined fibrate-statin treatment arm during the trial period 
resulted in a statistically significant beneficial legacy 
effect on all-cause mortality observed in the post-trial 
period (adjusted HR = 0.65, 95% CI 0.45–0.94; P = 0.02, 
other effects not statistically significant). Long-term ben-
eficial effects were also found when trial and follow up 
periods were combined (9.7  years follow-up from time 
of randomization) for all-cause mortality, CVD mortality 
and major coronary heart disease events (effects on CVD 
Table 1 Characteristics of the participants at baseline and 1st post-trial visit
Plus–minus values are mean ± SD
HbA1c glycated hemoglobin A1c, SBP systolic blood pressure, CHOL total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density 
lipoprotein cholesterol, VLDL-C very low-density lipoprotein cholesterol
Characteristics Baseline P 1st post‑trial visit P
Fenofibrate (n = 484) Placebo (n = 456) Fenofibrate (n = 395) Placebo (n = 370)
Age 61.4 ± 6.2 62.2 ± 6.7 0.04 67.2 ± 6.3 67.6 ± 6.6 0.32
Sex 0.96 0.59
 Male 388 (80.2%) 364 (79.8%) 319 (80.8%) 292 (78.9%)
 Female 96 (19.8%) 92 (20.2%) 76 (19.2%) 78 (21.1%)
Years of diabetes 9.2 ± 6.6 9. 6 ± 6.6 0.37 14.6 ± 6.5 15.2 ± 6.6 0.22
Ethnicity 0.17 0.51
 White 365 (75.4%) 362 (79.4%) 305 (77.2%) 294 (79.5%)
 Non-White 119 (24.6%) 94 (20.6%) 90 (22. 8%) 76 (20.5%)
CVD history 0.93 0.98
 Yes 195 (40.3%) 186 (40.8%) 153 (38.7%) 142 (38.4%)
 No 289 (59.7%) 270 (59.2%) 242 (61.3%) 228 (61.6%)
BG trial assignment 0.36 0.36
 Intensive group 251 (51.8%) 222 (48.7%) 203 (51.4%) 177 (47.8%)
 Standard group 233 (48.2%) 234 (51.3%) 192 (48.6%) 193 (52.2%)
HbA1c (%) 8.4 ± 1.1 8.4 ± 1.0 0.94 7.9 ± 1.9 7.6 ± 1.3 0.07
SBP (mm Hg) 134.1 ± 17.6 133.9 ± 18.6 0.87 131.0 ± 17.1 131.8 ± 17.3 0.66
CHOL (mg/dl) 187.0 ± 38.5 189.0 ± 42.1 0.45 154.6 ± 42.5 152.8 ± 32.8 0.64
TG (mg/dl) 327.2 ± 125.3 325.0 ± 154.2 0.81 216.6 ± 124.1 222.7 ± 115.2 0.61
VLDL-C (mg/dl) 61.2 ± 18.6 61.2 ± 25.4 0.97 41.4 ± 20.8 42.63 ± 20.1 0.55
LDL-C (mg/dl) 96.3 ± 32.0 98.4 ± 32.9 0.34 79.2 ± 32.7 76.6 ± 26.1 0.38
HDL-C (mg/dl) 29.5 ± 3.8 29.5 ± 3.7 0.76 33.9 ± 7.3 33.6 ± 7.2 0.60
Table 2 Trial adherence and  use of  lipid-modifying 
medication post-trial





Year 1 Fenofibrate/placebo 91.4 91.2
Simvastatin 94.5 95.5
Year 2 Fenofibrate/placebo 88.8 91.5
Simvastatin 93.6 96.1
Year 3 Fenofibrate/placebo 87.2 90.2
Simvastatin 91.3 92.9
Year 4 Fenofibrate/placebo 85.3 86.3
Simvastatin 92.9 92.5
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mortality and all-cause mortality were statistically signifi-
cant). Kaplan–Meier cumulative event curves for primary 
outcome and selected secondary outcomes are consistent 
with findings from the Cox models and are presented in 
Fig. 2. Sensitivity analyses adjusting for medication use of 
post-trial follow-up and for other potential confounders, 
using inverse probability weighting, resulted in similar 
findings (Additional file 1: Table S1). 
Discussion
We found that patients with dyslipidemia who were ran-
domized to statin-fibrate treatment during the trial had 
higher survival in the 5  years after the trial than those 
randomized to statin-placebo. This effect was observed 
despite similar achieved lipid profile during the extended 
observational follow-up, which suggests a legacy effect of 
fibrate add-on therapy on all-cause mortality. Although 
estimated legacy effects on all other outcomes were 
not statistically significant, the effect estimates suggest 
that improved survival is likely to be largely explained 
through effects on CVD. No information was available on 
non-CVD causes of death, which meant we were not able 
to explore other possible explanations for the all-cause 
mortality reduction. The overall long-term benefits for 
CVD mortality appeared to be driven by both within-
trial treatment effects and legacy effects emerging post-
trial. Other studies suggest that fibrates may also have 
beneficial effects on microvascular outcomes, including 
Fig. 1 Plasma lipid levels of patients with dyslipidemia at each study visit. The line charts show the means of lipid levels and corresponding 95% 
CI at 1/2/3/4 year, exit visit, 1st post-trial visit and last post-trial visit. HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein 
cholesterol, VLDL-C very low-density lipoprotein cholesterol, PT1 first post-trial clinic visit, PT3 last post-trial clinic visit
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Fig. 2 Kaplan–Meier cumulative event curves for primary and secondary outcomes. The Kaplan–Meier curves display the time to event for the 
all-cause mortality (a) and cardiovascular mortality (b), nonfatal myocardial infarction (c), stroke (d), congestive heart failure (e) and a major coronary 
heart disease event (f) during trial period, post-trial and the entire study period. The numbers of individuals at risk are shown for each time point
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on renal and liver function [29], but we didn’t have data 
to explore this.
During the trial period, fibrate add-on therapy reduced 
triglycerides and VLDL-C beyond that achieved with 
statins only, but HDL-C was increased by only a limited 
amount. These findings have been observed in other clin-
ical trials of fibrate—for example in the Fenofibrate Inter-
vention and Event Lowering in Diabetes (FIELD) study, 
allocation to fenofibrate resulted in a 20% reduction of 
baseline TG, but HDL-C remained almost unchanged at 
study close [30–32]. The improvement of the triglyceride-
rich environment may explain the reduced risk of CVD 
observed during the trial period in these patients [15, 
33]. As most of participants in active arm discontinued 
the use of fibrate in post-trial, between group differences 
in triglycerides and VLDL-C soon disappeared. This sug-
gests continuous treatment is necessary to maintenance a 
lower TRIG/VLDL-C.
Our findings on potential beneficial effects on CVD 
mortality reduction are supported by a recent report of 
a large propensity matched cohort study that found a 
(non-statistically significant) reduction in CVD mor-
tality associated with fibrate use [23]. Results from the 
ongoing Pemafibrate to Reduce Cardiovascular Out-
comes by Reducing Triglycerides in Patients with Dia-
betes (PROMINENT) study will also provide evidence 
regarding short term effectiveness; further follow up 
studies are needed for longer term legacy effects [34, 
35].
Our study has several limitations. First, our analysis 
examined a relatively small subset of the full trial and the 
power to detect smaller effects is limited [36]. The find-
ings for this prespecified subgroup with dyslipidemia 
must be interpreted with caution, and further larger 
studies in people with dyslipidemia are needed. Second, 
as in ACCORD, the diabetic dyslipidemia was defined in 
a data-driven manner, however the thresholds used are 
similar to other definitions of dyslipidemia [3, 37]. Third, 
we used the investigators reported (unadjudicated) cause 
of death data for both trial and post-trial periods. A pre-
vious report from ACCORD study group has shown the 
CVD mortality was under-reported by the investigators 
compared to the adjudicated Committee [28], suggesting 
potential misclassification of cause of death using these 
data. Fourth, although we adjusted analyses for potential 
imbalance between randomized groups in confound-
ers during the post-trial period, measurement error in 
these, and the presence of other unmeasured confound-
ers could bias our estimates [22].
Conclusion
In conclusion, this secondary analysis found evidence 
of legacy effects of fenofibrate-statin combined therapy 
on all-cause mortality in diabetic patients with dyslipi-
demia. This finding suggests fibrate treatment may be 
an effective means of reducing residual cardiovascular 
risk in these patients.
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